New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on November 17, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lilly Endowment Inc, a major shareholder of Eli Lilly & Co, has recently sold 178,295 shares of the company’s stock. This transaction is valued at an impressive $75,907,041,574.
Recent Updates on LLY stock
Eli Lilly & Co. has announced updates on several ongoing clinical studies, which could significantly impact its stock performance. The company is conducting a Phase 2 study on brenipatide for smoking cessation, a Phase 3 study on baricitinib for preserving beta-cell function in type 1 diabetes, and another Phase 3 study to delay type 1 diabetes onset. Additionally, a Phase 4 study on the long-term safety of pirtobrutinib in chronic lymphocytic leukemia and a Phase 3 trial on Vepugratinib for advanced bladder cancer are underway. These studies aim to expand Eli Lilly’s treatment portfolio in smoking cessation, diabetes, and oncology, potentially positioning the company favorably against competitors. Success in these trials could enhance investor sentiment and influence stock performance positively.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
Eli Lilly & Co’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The company’s robust revenue growth, market share gains, and strategic pipeline advancements are key strengths. However, high leverage, declining cash flow metrics, and a premium valuation present potential risks.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
YTD Price Performance: 33.80%
Average Trading Volume: 3,853,258
Technical Sentiment Signal: Buy
Current Market Cap: $969.3B